Turkey is an emerging economy in almost all sectors, and especially in pharmaceuticals. Turkey has had clinical trial legislation for a long time. There are also clinical trial regulations and guidelines. Turkey has taken major steps towards harmonizing its legislation with the European Union in the fi eld of clinical research and currently Turkish regulations are totally in line with EC Directives (EC 2001/20 and EC 2005/28). The main objective of this article is to discuss the relevant parts of the minimum necessary information on current legislation related to clinical trials in Turkey, instead of detailing all current legislation related to the clinical trials in Turkey as of 2011. Details of legislation mentioned in the article can be found in the Offi cial Gazette and on corporate websites. In order to protect the rights, well-being, and health of the subjects in accordance with internationally valid scientifi c and ethical standards, clinical trials must be performed within these legal regulation frameworks and attention should be paid to the presentation of quality and reliable data.
Turkey offers good opportunities with regard to the high number of enthusiastic physicians and, moreover, the higher availability of treatment-naive patients interested in participating in clinical trials.
Turkey is in the review phase to join the European Union and has undergone many important reforms involving patients rights, criminal law, specialized biotech drug dispensing acts, and so on. Along with policies and visions for scientifi c and technological development put forward by the EU in the mid-1990s, Turkey has taken major steps towards harmonizing with the EU in the fi eld of clinical research and drug trials.
Turkey is known for its unique geographical location, straddling the continents of Europe and Asia with borders to 7 countries: Greece and Bulgaria to the northwest, Syria to the south, Iraq to the southeast, and Armenia, Georgia, and Iran to the east. It is a bridge to Europe from Asia and the Middle East.
Turkey is an emerging economy in almost all sectors, and especially in pharmaceuticals. Turkey has had clinical trial legislation for a long time. There are also clinical trial regulations and guidelines. Turkey has taken major steps towards harmonizing its legislation with the EU in the fi eld of clinical research and, currently, Turkish regulations are totally in line with EC Directives (EC 2001/20 and EC 2005/28). Thus, there are ethics committees. According to the Turkish clinical trial legislation, after getting approval from an ethics committee, one needs to get permission for conducting clinical trials in Turkey from the Turkish Medicines and Medical Devices Agency (TMMDA). The TMMDA is working intensively to standardize ethics committee SOPs and applications.
Turkey has a population of 75 million people (median age: 30 years). Turkey also has well-reputed research sites with strong technical infrastructure capabilities at international standards.
The Clinical Trials Department of the TMMDA reviews clinical trials in Turkey. Under the Clinical Trials Department there are a phase evaluation unit, bioequivalence/ bioavailability evaluation unit, and a post-marketing surveillance evaluation unit.
The main objective of this article is to discuss the relevant parts of the minimum necessary information on current legislation related to clinical trials in Turkey, instead of detailing all current legislation related to the clinical trials in Turkey as of 2011. Details of legislation mentioned in the article can be found in the Offi cial Gazette and on corporate websites.
The distribution of clinical drug trials conducted in accordance with legal regulation in Turkey between 01.01.1997 and 31.12.2012 is shown in Table 1 . Table 1 shows that there is a decrease in the number of clinical trials in 2010 and 2011; this is because of some legal problems about regulation of clinical trials in Turkey.
If we look the distribution of studies, the fi rst 6 major areas are oncology, anesthesiology, the central nervous system, the cardiovascular system, endocrinology, and infectious diseases, followed by others.
When we analyze the number of studies related to hematology that were conducted in 2012, there were 6 Phase II studies, 18 Phase III studies, 1 Phase IV study, and 1 PMS study. In oncology these numbers were 6 Phase II and 16 Phase III studies.
Before planning to conduct any clinical trial on human subjects in Turkey, being informed of the following main legal regulations will be helpful.
In the Turkish Constitution of 1982, in the second part on fundamental rights and duties, article 17 of chapter 1, "Personal Inviolability, Material and Spiritual Entity of the Individual", clearly states that clinical trials cannot be conducted without consent of the subject.
In Act No. 1219 on Medicine and Practicing of the Medical Profession, article 70 states that clinical trials cannot be conducted without consent, and if clinical trials on children or persons with legal disability are planned, obtaining consent of the legal guardian is obligatory.
Article 10 of Health Services Principal Act No. 3359 should also be known.
As mentioned in the second paragraph of "Experiments on Humans", the 90th article of Act No. 5237 of the Turkish Penal Code, in order to rule out penal responsibility of a consent-based scientifi c experiment on a human being, it should be known by the subject, as mentioned in the fi rst paragraph, that a "person conducting a scientifi c experiment on human beings will be sentenced to imprisonment for a term of from one to three years".
If trials on children are planned, the 31/3/2005 -5328/7 amended article of the Turkish Penal Code should be known. Accordingly, in order to reach the desired objective, scientifi c data obtained as a result of the research should necessitate conduct of the research on children; along with the consent of any child who is able to declare consent, the Especially if clinical trials involve special populations (such as disabled persons or children), the following articles of the Turkish Civil Code will be helpful to explain and obtain subjects' informed consent: article 9-13 for legal capacity, article 14-16 for legal incapacity, article 23 for the protection of personality, article 404-410 for cases necessitating guardianship, article 411-412 for authority on guardianship procedures, article 413-416 for assignment of guardian, and article 417-418 for restraints of guardianship. Articles 10 and 11 of the Medical Deontology Regulation highlight that it should be declared that the performed procedure is research and should be previously tested on experiment animals.
Regulations

Regulation on clinical trials issued on 13 April 2013
and numbered 28617 in the Offi cial Gazette, should be known in all of its details.
2. In No. 28307 of the Offi cial Gazette, dated 26 August 2011 and published on "Regulation on Promotion of Human Medicinal Products", it is stated in section ğ of the 9th subparagraph of the 6th article that the license/ authorization holder will deliver human medicinal products, laboratory kits, and other such donations to be used in clinical trials directly to the responsible investigator. The 4 th subparagraph of the 7 th article clearly states that domestic and foreign investigator meetings of national and international multicenter clinical trials sponsored by the license/authorization holder will not be considered as congress or symposium participation, the nature of the meeting should be clearly stated in the submitted application, and it should be noted that the meeting is organized for this reason. Section g of the 1st subparagraph of the 9th article states that promotional samples are not allowed to be used as investigational products in clinical trials. • Gene therapy studies
In order to protect the rights, well-being, and health of subjects in accordance with internationally valid scientifi c and ethical standards, clinical trials must be performed within this legal regulation framework and attention should be paid to presenting quality and reliable data.
Turkey offers good opportunities with regard to the high number of enthusiastic physicians and, moreover, a higher availability of treatment-naive patients interested in participating in clinical trials.
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